InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
1
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-44.6%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the complete record of transactions filed by Bruck Claudine, 董事. Officer active across 2 companies, notably Navidea Biopharmaceuticals, INC.. Cumulatively, 6 disclosures have been recorded. Split: 1 buy · 0 sell. Total volume traded: €4k. Activity tracked since 30 June 2021. The latest transaction was filed on 10 September 2025 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Bruck Claudine
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
7,142 股@ US$0.145.2% 占其流量Common StockSEC:0001104659-25-109904:0
00Common StockSEC:0001104659-23-120749:0
1,000 股@ US$6.0727.8% 占其流量Common StockSEC:0001104659-23-120299:0
500 股@ US$12.6128.9% 占其流量Common StockSEC:0001104659-23-044208:0
181 股@ US$27.6626.2% 占其流量Common StockSEC:0001415889-21-004864:0
标准退出：2022年1月9日 (T+90)
3,969 股0Common StockSEC:0001437749-21-016596:0
6 条申报中的 6 条
About Bruck Claudine
Claudine Bruck is a Director at NAVIDEA BIOPHARMACEUTICALS, INC. and Annovis Bio, Inc. She brings valuable expertise in the biopharmaceutical field, contributing to the strategy and governance of these companies. Her role as a director allows her to actively participate in strategic decision-making and oversee operations, thereby fostering growth and innovation.
